gefitinib,Osimertinib
astrazeneca
['nsclc', 'tagrisso', 'sclc', 'biomarker', 'marker ', 'astrazeneca']
repeat biomarker testing informs next steps for treatment-resistant egfr-mutant nsclc patients. studies at esmo showed the importance of repeat biomarker testing to guide treatment after resistance to astrazeneca's tagrisso, but tissue-based testing... 